Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Self-citationBurr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610 · cited 6×
“The effect of 1000 mg/d EPAþDHA supplementation on a population with baseline intake of 83 mg/d (a reasonable estimate of the U.S. adult intake at the time of DART, as described above) would have a much larger protective effect than that observed in the ORIGIN trial [4].”
BackgroundInfluentialYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H. A., Johnson, L., Franco, O. H., Butterworth, A. S., Forouhi, N. G., Thompson, S. G., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1788 · Cited by 1,139
The Omega-3 Index: A new risk factor for death from coronary heart disease?
Harris, W. S., & von Schacky, C. (2004) · Preventive Medicine · doi:10.1016/j.ypmed.2004.02.030 · Cited by 1,111
Self-citationn–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Siscovick, D. S. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530170043030 · Cited by 920
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
He, K., Song, Y., Daviglus, M. L., Liu, K., Van Horn, L., Dyer, A. R., & Greenland, P. (2004) · Circulation · doi:10.1161/01.cir.0000132503.19410.6b · Cited by 764 · cited 1×
“A substantial body of epidemiological evidence for the association between reduced cardiac events/mortality and higher intakes (mostly from fish) and blood levels of LC omega-3 fatty acids have accumulated since that time [31–33].”
BackgroundTurner, L., Shamseer, L., Altman, D. G., Weeks, L., Peters, J., Kober, T., Dias, S., Schulz, K. F., Plint, A. C., & Moher, D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000030.pub2 · Cited by 740
Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Galan, P., Kesse-Guyot, E., Czernichow, S., Briancon, S., Blacher, J., Hercberg, S., & for the SU.FOL.OM3 Collaborative Group (2010) · BMJ · doi:10.1136/bmj.c6273 · Cited by 457
Rees, D., Miles, E. A., Banerjee, T., Wells, S. J., Roynette, C. E., Wahle, K. W., & Calder, P. C. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.331 · Cited by 401
Self-citationKwak (2012) · doi:10.1001/archinternmed.2012.262 · Cited by 368
Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake
Leaf, A., Albert, C. M., Josephson, M., Steinhaus, D., Kluger, J., Kang, J. X., Cox, B., Zhang, H., & Schoenfeld, D. (2005) · Circulation · doi:10.1161/circulationaha.105.549527 · Cited by 364
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316
Mozaffarian, D., Lemaitre, R. N., King, I. B., Song, X., Huang, H., Sacks, F. M., Rimm, E. B., Wang, M., & Siscovick, D. S. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00003 · Cited by 283
Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging
Tan, Z. S., Harris, W. S., Beiser, A. S., Au, R., Himali, J. J., Debette, S., Pikula, A., DeCarli, C., Wolf, P. A., Vasan, R. S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318249f6a9 · Cited by 265
Self-citationStonehouse, W., Conlon, C. A., Podd, J., Hill, S. R., Minihane, A. M., Haskell, C., & Kennedy, D. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.053371 · Cited by 252
Combination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240
Effect of low-to-moderate amounts of dietary fish oil on neutrophil lipid composition and function
Healy, D. A., Wallace, F. A., Miles, E. A., Calder, P. C., & Newsholme, P. (2000) · Lipids · doi:10.1007/s11745-000-0583-1 · Cited by 227 · cited 2×
“Trials with LC omega-3 fatty acid supplements have demonstrated the possibility of marked increases in EPA and DHA content of blood lipids [42,84,89–95], various blood cells types including platelets [42,89,96], white cells [42,84,93,94,97,98] and red cells [42,91,92,95], and various tissues including skeletal muscle…”
BackgroundSelf-citationRelationships between plasma fatty acid composition and coronary artery disease.
Itakura, H., Yokoyama, M., Matsuzaki, M., Saito, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Kita, T., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5876 · Cited by 218
Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966168 · Cited by 201 · cited 1×
“Findings from recent meta-analyses of RCT data from trials with LC omega3 fatty acid interventions have provided evidence for a modest benefit on risk for cardiac death, but have generally failed to show significant reductions in other cardiovascular disease (CVD) outcomes [36–39].”
BackgroundTemporal changes in human skeletal muscle and blood lipid composition with fish oil supplementation
McGlory, C., Galloway, S. D. R., Hamilton, D. L., McClintock, C., Breen, L., Dick, J. R., Bell, J. G., & Tipton, K. D. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.03.001 · Cited by 130 · cited 1×
“Trials with LC omega-3 fatty acid supplements have demonstrated the possibility of marked increases in EPA and DHA content of blood lipids [42,84,89–95], various blood cells types including platelets [42,89,96], white cells [42,84,93,94,97,98] and red cells [42,91,92,95], and various tissues including skeletal muscle…”
BackgroundWen, Y. T., Dai, J. H., & Gao, Q. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.12.004 · Cited by 98
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83 · cited 1×
“primarily those with severe hypertriglyceridemia [49,50].”
Self-citationSaito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.002 · Cited by 29
Cited by
Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020
Innes, J. K., & Calder, P. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041362 · Cited by 365
Self-citationBlood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies
Harris, W. S., Tintle, N. L., Imamura, F., Qian, F., Korat, A. V. A., Marklund, M., Djoussé, L., Bassett, J. K., Carmichael, P.-H., Chen, Y.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22370-2 · Cited by 244
Self-citationEffect of Omega-3 Dosage on Cardiovascular Outcomes
Bernasconi, A. A., Wiest, M. M., Lavie, C. J., Milani, R. V., & Laukkanen, J. A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.08.034 · Cited by 237
Self-citationImportance of EPA and DHA Blood Levels in Brain Structure and Function
von Schacky, C. (2021) · Nutrients · doi:10.3390/nu13041074 · Cited by 174
O’Mahoney, L. L., Matu, J., Price, O. J., Birch, K. M., Ajjan, R. A., Farrar, D., Tapp, R., West, D. J., Deighton, K., & Campbell, M. D. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0740-x · Cited by 157
“Quantifying the fatty acid composition of blood in n-3PUFA supplementation trials offers an objective measure of compliance and assessment of interindividual variability [51].”
Metadata
- Authors
- Rice, H. B., Bernasconi, A., Maki, K. C., Harris, W. S., von Schacky, C., & Calder, P. C.
- Venue
- Prostaglandins, Leukotrienes and Essential Fatty Acids
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 107
- Pages
- 30-42
- ISSN
- 0952-3278 (ISSN-L)
- OpenAlex
- W2268535495
- Cited by
- 56
- References
- 35
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.